News for Savara Inc. (SVRA)

On December 31, 2024, Vestal Point Capital, LP (Trades, Portfolio), a prominent investment firm, executed a noteworthy transaction by acquiring an additional 2,

[url="]Savara Inc.[/url] (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of induceme

SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges

[url="]Savara Inc.[/url] (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of induceme

Savara initiated a rolling BLA submission for MOLBREEVI to treat aPAP, with completion expected in Q1 2025, potentially boosting its stock. Read our full stock analysis here.

[url="]Savara Inc[/url]. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of induceme

On November 19, 2024, Joseph Mccracken, a Director at Savara Inc (SVRA), purchased 20,000 shares of the company. Following this transaction, the insider now hol

Savara director Joseph McCracken acquires $59,071 in common stock

On November 18, 2024, David Ramsay, Director at Savara Inc (SVRA), purchased 100,000 shares of the company, as reported in a recent SEC Filing. Following this t

Overview of the Recent Transaction On September 30, 2024, Wellington Management Group LLP made a significant addition to its investment portfolio by acquiring 1

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act ® Airing on Lifetime ® TV

Savara maintains buy stock rating on aPAP drug potential

Savara appoints Braden Parker as Chief Commercial Officer

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 196 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information ...

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company...

/PRNewswire/ -- The "Global Targeted Drug Delivery Market by Disease Type, Application, End-user, and Region - Size, Share, Outlook, and Opportunity Analysis,...

Read Analysts’ Upgrades for June 1st (BME, BMRRY, BPMC, DHR, DLTR, DMRC, FINV, FMX, GCHEF, HBCP) at ETF Daily News

This article focuses on the influences towards a biotech company's share price, rather than their value. Read what to know about biotech catalysts here.